How Healthcare Claims Data Predicted GLP-1 Revenue 30 Days Before Earnings

It was the most anticipated drug launch in a generation. By late 2022, Ozempic had crossed from medical journals into mainstream culture, and by 2023, Novo Nordisk and Eli Lilly had become the two most talked-about names on every healthcare earnings call in the world. Wall Street analysts were scrambling to revise their models. Most of them were late.

The hedge funds that got it right were not operating on superior instincts. They were operating on superior data.

This is a story about how real-time healthcare claims data — specifically, T+1 daily prescription claims — gave institutional investors a clear, quantitative picture of GLP-1 revenue growth 30 days before it showed up on an earnings call. The data existed. It was accessible. And the managers who used it built positions that consensus had not yet priced in.

The Signal Was in the Scripts

GLP-1 agonists — the drug class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are unusual in one respect that matters deeply to investors: their revenue is generated at the point of dispensing. When a patient fills an Ozempic prescription at CVS, a claim record is created that day. That record flows through the pharmacy switch system, reaches the payer for adjudication, and enters aggregated claims datasets within 24 hours of being processed.

That prescription is Novo Nordisk revenue. It was recognized before the quarter ended. And with T+1 claims data, it was visible to institutional investors by the following morning.

IMX Data's longitudinal dataset — 100 billion+ claim events covering 330 million+ patients — captures the GLP-1 story with a clarity that no other data source can match. From 2015 to 2025, total U.S. GLP-1 claims reached 231.6 million, representing a 3,498% increase from the 2015 baseline. Total all-time market spend crossed $293 billion. In the most recent completed quarter alone, GLP-1 market spend hit $26.1 billion.

These are not numbers an analyst modeled from IMS trend lines and management guidance. They are counts of actual prescriptions, dispensed to actual patients, at actual prices.

What the Data Showed — Before the Earnings Call

Walk through the mechanics of a real scenario. Suppose it is mid-November 2024 — six weeks before the end of Q4. Novo Nordisk is expected to report earnings in early February 2025. The sell-side consensus for Ozempic revenue is roughly in line with Q3 trends, with modest sequential growth.

A fund running IMX Data's daily claims feed wakes up each morning to an updated view of GLP-1 prescription volume, by drug, by state, by payer type. Their analysts observe three things that the consensus model does not yet reflect:

First, Ozempic's weekly prescription counts are running materially above the prior-quarter weekly average — not by 4% or 5%, but by a directionally significant margin. The signal is visible because the data is daily. It doesn't require waiting for a weekly batch or a monthly rollup; it accumulates every morning.

Second, cash-pay claims are elevated relative to insured claims. This is a nuanced but powerful signal. Cash-pay prescriptions — patients paying out of pocket without insurance — appear in open claims data faster than adjudicated insurance claims, which must clear payer review cycles. When cash-pay claim volume accelerates ahead of insured claim volume, it is a leading indicator: the insured claims will follow.

Third, geographic variation reveals something the national average obscures. Ozempic's strongest growth was not uniform. State-level data shows disproportionate acceleration in markets where Novo Nordisk's commercial team had focused rebate negotiations with large payers.

The Scale of the GLP-1 Opportunity — By the Numbers

For a portfolio manager, these numbers answer questions that earnings transcripts leave open. When Novo Nordisk's CFO says demand "remains robust," the claims data tells you exactly how robust, by which drug, in which states, in which week.

The Market Share Story That Analysts Missed

The GLP-1 market share race between Novo Nordisk and Eli Lilly is one of the most closely watched competitive dynamics in modern biopharma. But aggregate market share numbers mask the velocity of share shifts — and velocity is what drives quarterly revenue variance.

IMX Data's state-level granularity makes share shift velocity visible. In several states, tirzepatide (Mounjaro/Zepbound) gained double-digit share percentage points quarter over quarter as Eli Lilly's commercial infrastructure matured and payer negotiations concluded.

A fund with national-level weekly data sees: Eli Lilly is gaining share. A fund with state-level daily data sees: Eli Lilly is gaining share in these 14 states at this rate, while Novo Nordisk is holding share in these 12 states. These are different investment theses — different drugs, different exposure sizes, different hedge ratios.

Cash-Pay as a Leading Indicator

One of the most actionable insights in IMX Data's GLP-1 analysis is the role of cash-pay claims as a forward signal. Insured prescription claims are subject to payer adjudication, which can take days to weeks to process fully. Cash-pay claims move through the system faster and appear in open claims data with lower latency than insured claims.

A fund that tracks cash-pay claims separately from insured claims gets a 2–4 week head start on insured claim trends. On a 90-day quarter, that is a meaningful fraction of total visibility.

What This Means for Portfolio Construction

A revenue model built on T+1 daily claims data has several structural advantages:

Frequency: Daily data allows 60–70 data points per quarter versus 1–2 management updates.

Independence: The signal is derived from actual patient behavior, not management commentary or analyst consensus.

Granularity: State-level and payer-type breakdowns enable attribution analysis — understanding why a drug is growing or declining, not just whether it is.

Early detection: Cash-pay trends and geographic leading markets provide 2–4 week advance signal on trends that appear nationally 30 days later.

Backtestability: IMX Data's 11+ years of historical claims data allows funds to validate signal-to-revenue predictive models before deploying capital.

The Bottom Line

The GLP-1 drug class did not surprise attentive institutional investors who were using high-quality claims data. The growth trajectory — 3,498% over a decade, $293 billion in cumulative spend, Ozempic alone generating 70.5 million claims — was visible in the data long before it was visible in analyst models or earnings reports.

Healthcare claims data is the closest thing institutional investors have to a real-time revenue counter for pharmaceutical companies. The funds that recognized that early, and acquired the best available dataset, had a structural information advantage throughout one of the most significant drug launches of the past decade.

The next GLP-1 — a drug class that reshapes a major disease category and generates hundreds of billions in new revenue — will generate the same signals. The question is which funds will be positioned to read them.

IMX Data provides institutional-grade healthcare claims data for buy-side equities investors. The dataset covers 100B+ claim events, 330M+ patients, 1,500+ healthcare tickers, with T+1 daily delivery and 11+ years of historical data. SOC 2 certified. Pricing starts at $1.50M/year.